Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

ible for the development

of the Staccato Electric Multiple Dose device, and the Company has the

exclusive right to manufacture the product for clinical development

and commercial supply.

-- AZ-007 (Staccato zaleplon). Alexza is developing AZ-007 for the

treatment of insomnia in patients who have difficulty falling asleep,

including patients who awake in the middle of the night and have

difficulty falling back asleep. In March 2008, Alexza completed

enrollment in a Phase 1 clinical trial of 40 healthy volunteers at a

single U.S. clinical center. The purpose of this trial was to assess

the safety, tolerability and pharmacokinetic parameters of a single

dose of AZ-007. Using a double-blind, randomized, dose-escalation

trial design, 4 doses of AZ-007 (ranging from 0.5 to 4.0 mg) were

compared to placebo.

In April 2008, Alexza announced positive initial results from the Phase 1 study. AZ-007 delivered an IV-like pharmacokinetic profile with a median time to peak venous concentration (Tmax) of 1.6 minutes. Zaleplon exposure was dose proportional across the 4 doses studied, as calculated by power analysis. Pharmacodynamics, measured as sedation self-assessed on a 100 mm visual-analog scale, showed onset of effect as early as 2 minutes after dosing with AZ-007. There were no serious adverse events. The most frequently reported adverse events in subjects receiving AZ-007 were dizziness and somnolence. These data indicate a rapid onset of effect, apparently directly related to the IV-like pharmacokinetics, and showed that AZ-007 was generally safe and well tolerated in this population of healthy volunteers.

Conference Call Information

Alexza will host a conference call today at 4:30 p.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to al
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... JOSE, Calif. , Sept. 15, 2014 /PRNewswire/ ... Proposals (RFP) for flexible, printed product demonstrators (demos) ... a two-stage RFP process with pre-proposals due on ... January 2015.  Funds for proposals ultimately selected are ... and have a significant cost share by the ...
(Date:9/15/2014)... downhill fast when a patient has sepsis, a life-threatening ... patient,s blood -- often too fast for antibiotics to ... and developed by a team at Harvard,s Wyss Institute ... doctors treat sepsis. , "Even with the best ... units at least 30 percent of the time," said ...
(Date:9/15/2014)... An interdisciplinary team of researchers led by Northeastern ... constructing precise inter-nanotube junctions and a variety of ... is facile and easily scalable, which will allow ... nanotube networks for use in applications ranging from ... everything from cars to sports equipment. , Their ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that ... is scheduled to deliver a presentation on,Wednesday, ... Process for,the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" ... Production Conference in Cologne, Germany. The,conference runs ...
... for controlling the magnetic properties of a commonly used ... research published recently in Advanced Materials. , Scientists have ... dye known as Metal Phthalocyanine, or MPc, with the ... still in its infancy, researchers claim that the ability ...
... ), a leader in the discovery and development of safe ... is scheduled to,present at the Bank of Montreal,s 2007 Focus ... and CFO of Bionovo, Inc., will,take place on Wednesday, December ... Hotel in New York City., To access a live ...
Cached Biology Technology:Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference 2Blue dye could hold the key to super processing power 2Blue dye could hold the key to super processing power 3
(Date:9/15/2014)... PULLMAN, Wash.Washington State University researchers have found "the most ... that can be used to transfer valuable genes ... the way for breeders to develop wheat varieties with ... a legion of genetic tools that can reduce crop ... hurdles and controversy of Genetically Modified Organisms, or GMOs., ...
(Date:9/15/2014)... years after it formed may have been surprisingly similar ... active crustal plates. , This alternate view of Earth,s ... new support from the first detailed comparison of zircon ... with those formed contemporaneously in Iceland, which has been ... , The study was conducted by a team of ...
(Date:9/15/2014)... published account where hippopotamuses are demonstrably shown swimming or ... But if they can,t swim, how did they reach ... models for the methods, patterns, and timing of the ... and Madagascar) may need to be reconsidered. , "Although ... mainland are not currently supported by positive geological evidence, ...
Breaking Biology News(10 mins):WSU researchers find 'most famous wheat gene' 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... just hidden from view, a mystery atom in the ... hindered scientists, ability to study the enzyme fully. ... Serena DeBeer, Cornell assistant professor of chemistry and chemical ... spectroscopy and computational modeling to reveal carbon as the ...
... Nov. 17, 2011 Minntech Corporation has been named ... Sciences - Established Companies Category. Presented by the Minnesota ... and individuals who have played a significant role in ... futures of people living around the world. ...
... hand-weeding and/or herbicide application, controlling weeds is one of ... have made hand-weeding prohibitive as the sole method of ... less expensive, non-target herbicide loss can be as high ... the economic and environmental impact of weed problems, nursery ...
Cached Biology News:In an enzyme critical for life, X-ray emission cracks mystery atom 2Minntech Corporation Receives 2011 Tekne Award 2Minntech Corporation Receives 2011 Tekne Award 3Biodegradable mulches successfully control weeds in container-grown arborvitae 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: